Abstracts Archive - Page 1979 of 2607 - ACR Meeting Abstracts

Abstract Number: 1623 • 2015 ACR/ARHP Annual Meeting
Genome-Wide Association Study of DNA Methylation in Th1 and Th17 Cells in Rheumatoid Arthritis
Katharina Stutzer¹, Fausto Pirronello¹, Simone Wahl², Hendrik Schulze-Koops¹, Alla Skapenko¹ and Jan Leipe³, ¹Division of Rheumatology and Clinical Immunology, University of Munich, Munich, Germany, ²Research Unit of Molecular Epidemiology, Helmholtz Zentrum München, Munich, Germany, ³Division of Rheumatology and Clinical Immunology, Med. Klinik und Poliklinik IV, University of Munich, Munich, Germany
Background/Purpose: Rheumatoid arthritis (RA) is a common autoimmune disease characterized by systemic inflammation. Although the understanding of the pathogenesis is incomplete, there is substantial evidence…
Abstract Number: 1624 • 2015 ACR/ARHP Annual Meeting
Epigenetic Profiling of CD14+ and CD16+ Monocyte Subtypes in Rheumatoid Arthritis. Alterations Related to Cardiovascular Disease and Endothelial Dysfunction
Nuria Barbarroja^1,2, Patricia Ruiz-Limon¹, Carlos Perez-Sanchez¹, Yolanda Jiménez Gómez¹, MariCarmen Abalos-Aguilera¹, Pedro Segui³, Pilar Font¹, Ángeles Aguirre Zamorano¹, Jerusalem Calvo-Gutierrez¹, Rafaela Ortega¹, M. Carmen Castro Villegas¹, Eduardo Collantes-Estévez¹, Alejandro Escudero-Contreras¹ and Chary Lopez-Pedrera¹, ¹IMIBIC-Reina Sofia University Hospital, Rheumatology Unit, Cordoba, Spain, ²Rheumatology Unit, IMIBIC-Reina Sofia University Hospital, Cordoba, Spain, ³IMIBIC-Reina Sofia University Hospital, Radiology Unit, Cordoba, Spain
Background/Purpose: Monocytes play a key role in the pathogenesis of the cardiovascular disease (CVD). Three monocyte subsets have been described based on their CD14 and…
Abstract Number: 1625 • 2015 ACR/ARHP Annual Meeting
Role of Macrophages in the Cardiovascular Disease Associated to Rheumatoid Arthritis: Effects of ANTI-CCPS in the Phenotypic Switching and the Insulin Signalling
Patricia Ruiz-Limon, Yolanda Jiménez Gómez, Carlos Perez-Sanchez, MariCarmen Abalos-Aguilera, M.Ángeles Aguirre Zamorano, Jerusalem Calvo-Gutierrez, Rafaela Ortega, Eduardo Collantes-Estévez, Alejandro Escudero-Contreras, Chary Lopez-Pedrera and Nuria Barbarroja, IMIBIC-Reina Sofia University Hospital, Rheumatology Unit, Cordoba, Spain
Background/Purpose: Macrophages play a key role in the pathogenesis of the rheumatoid arthritis (RA). Under certain stimulus conditions these cells are able to switch their…
Abstract Number: 1626 • 2015 ACR/ARHP Annual Meeting
The Association of HLA-DRB1 Alleles and Amino Acid Residues with Radiographic Severity in African Americans with Seropositive Rheumatoid Arthritis
Richard J. Reynolds¹, Maria I. Danila², Vincent A. Laufer³, Krishnan Raman¹, S. Louis Bridges Jr.⁴ and CLEAR Investigators, ¹Medicine, University of Alabama at Birmingham, Birmingham, AL, ²AL, ³Division of Clinical Rheumatology and Immunology, University of Alabama at Birmingham, Birmingham, AL, ⁴Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Val and Leu at HLA-DRB1 position 11 have been reported to be associated with radiographic progression in Caucasians with RA, independent of shared epitope…
Abstract Number: 1627 • 2015 ACR/ARHP Annual Meeting
HIF-1alpha Knockdown Down-Regulates Glycolytic Metabolism and Induces Rheumatoid Synovial Fibroblast Cell Death
Manuel J. Del Rey¹, Alicia Usategui¹, Álvaro Valín¹, María Sánchez-Aragó², José M. Cuezva², Carmen M. García-Herrero¹, María Galindo¹, Juan D. Cañete³, Francisco J. Blanco⁴, Gabriel Criado¹ and Jose L. Pablos¹, ¹Servicio de Reumatología, Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain, ²Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Investigación Hospital 12 de Octubre, Universidad Autónoma de Madrid, Madrid, Spain, ³Unitat d’Artritis, Servei de Reumatologia, Hospital Clínic de Barcelona and Institut d’Investigacions Biomèdiques August Pí i Sunyer, Barcelona, Spain, ⁴Laboratorio de Investigación Osteoarticular y del Envejecimiento, Instituto de Investigación Biomédica de A Coruña, INIBIC, A Coruña, Spain
Background/Purpose: Intense synovial fibroblast (SF) hyperplasia contributes to the chronic inflammation and osteoarticular destruction that characterizes rheumatoid arthritis (RA). Hypoxia-inducible factor 1α (HIF-1α) plays a…
Abstract Number: 1628 • 2015 ACR/ARHP Annual Meeting
A Novel Histone Deacetylase 6 Inhibitor, CKD-H059 Inhibits the Inflammatory Response in Rheumatoid Arthritis
Yu Jin Jang¹, Bo Ram Oh², Hyojin Lim³, Daekwon Bae³, Nina Ha³, Young il Choi⁴, Jin Kyun Park⁵, Eun Young Lee⁵, Eun Bong Lee⁵ and Yeong Wook Song^5,6, ¹Department of Molecular Medicine and Biopharmaceutical Sciences, BK 21 plus Graduate School of Convergence Science and Technology, and College of Medicine or College of Parmarcy, Seoul National University, Seoul, South Korea, ²Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, and College of Medicine, Seoul National University, Seoul, South Korea, ³Department of Pharmacology and Toxicology, CKD Research Institute, CKD Pharmaceutical Company, Seoul, South Korea, ⁴315-20 dongbaekjukjeon-daero, giheung-gu, Pharmacology lab, Hyo-Jong Research Laboratories, CKD Pharmaceutical Company, Yongin-si, South Korea, ⁵Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, South Korea, ⁶Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology and College of Medicine Seoul National University, Seoul, South Korea
Background/Purpose: Epigenetic changes including histone modification play an important role in development of rheumatoid arthritis (RA). Histone deacetylase inhibitor (HDACi) increases transcription of numerous genes…
Abstract Number: 1629 • 2015 ACR/ARHP Annual Meeting
Non-Interventional Clinical Study Investigating the Use of Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis in Germany – 3rd Interim Analysis
Matthias H. Thomas¹, Klaus Krüger², Pee Aries³, Martin Bohl-Buehler⁴, Jan Brandt-Juergens⁵, Verena Rickert⁶ and Siegfried Wassenberg⁷, ¹Medical Affairs, MSD Sharp & Dohme GmbH, Bünde, Germany, ²Praxiszentrum St. Bonifatius, München, Germany, ³Rheumatologie im Struenseehaus, Hamburg, Germany, ⁴Friedrich-Ebert-Str. 35, Rheumahaus, Potsdam, Germany, ⁵Praxis Brandt-Juergens/Karberg, Berlin, Germany, ⁶Medical Affairs, MSD Sharp&Dohme GmbH, Haar, Germany, ⁷Fachkrankenhaus, Ratingen, Germany
Background/Purpose: Golimumab (GOL) has shown its efficacy and safety in various randomized clinical trials with accurately selected patients. Data from daily clinical practice in Germany…
Abstract Number: 1630 • 2015 ACR/ARHP Annual Meeting
Progressive Destruction of Large Joints in Patients with Rheumatoid Arthritis Treated with Biologic Agents
Arata Nakajima¹, Masato Sonobe² and Koichi Nakagawa², ¹Orthopaedics, Toho University Sakura Medical Center, Sakura, Japan, ²Toho University Sakura Medical Center, Sakura, Japan
Background/Purpose: Many clinical trials have revealed that biologic agents inhibit destruction of small joints, however, there have been a few reports demonstrating their inhibitory effects…
Abstract Number: 1631 • 2015 ACR/ARHP Annual Meeting
Adverse Events to Biologic Agents in Elderly Patients with Rheumatoid Arthritis: Cohort with 13 Years of Follow-up
Zulema Rosales^1,2, Leticia Leon¹, Alejandro Gomez-Gomez², Lucía Arietti², Esperanza Pato Cour², José Luis Fernández Rueda¹, Juan A Jover² and Lydia Abasolo¹, ¹Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain, ²Rheumatology, Hospital Clínico San Carlos, Madrid, Spain
Background/Purpose: After more than a decade using biological agents (BA), is widely known their efficacy in the treatment of Rheumatoid Arthritis (RA) and their relationship…
Abstract Number: 1632 • 2015 ACR/ARHP Annual Meeting
Do RA Susceptibility Loci Predict Response to Methotrexate As First DMARD in Early RA?
Thomas Frisell¹, Saedis Saevarsdottir^2,3 and Johan Askling^1,4, ¹Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ²Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ³Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Rheumatology Unit, Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: Improved means to predict which RA patients will respond to methotrexate monotherapy, the preferred first line therapy in early RA, would allow patients to…
Abstract Number: 1633 • 2015 ACR/ARHP Annual Meeting
Long-Term Radiographic and Patient-Reported Outcomes Based on Clinical Disease Activity Index Responses with Tofacitinib at 6 Months
Vibeke Strand¹, Arthur Kavanaugh², Alan J. Kivitz³, Désirée van der Heijde⁴, Elaine Hoffmann⁵, Ermeg Akylbekova⁶, Arif Soonasra⁷, Mark Snyder⁷, Koshika Soma⁵, Eustratios Bananis⁷ and Josef S. Smolen⁸, ¹Biopharmaceutical Consultant, Portola Valley, CA, ²University of California, San Diego School of Medicine, LaJolla, CA, ³Altoona Center for Clinical Research, Duncansville, PA, ⁴Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁵Pfizer Inc, Groton, CT, ⁶Quintiles, Atlanta, GA, ⁷Pfizer Inc, Collegeville, PA, ⁸Medical University of Vienna, Vienna, Austria
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. This analysis assessed if patients achieving Clinical Disease Activity Index (CDAI) remission…
Abstract Number: 1634 • 2015 ACR/ARHP Annual Meeting
The Effects of Glucocorticoids on the Efficacy of Tofacitinib As Monotherapy and in Combination Therapy with Nonbiologic Dmards: An Analysis of Data from Six Phase 3 Studies
Roy Fleischmann¹, Christina Charles-Schoeman², Gerd Burmester³, Cristiano Zerbini⁴, Peter Nash⁵, Kenneth Kwok⁶, Koshika Soma⁷, Alan Mendelsohn⁸ and Eustratios Bananis⁸, ¹Metroplex Clinical Research Center, Dallas, TX, ²University of California, Los Angeles, CA, ³Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, ⁴Centro Paulista de Investigação Clinica, São Paulo, Brazil, ⁵Nambour Hospital, Sunshine Coast and Department of Medicine, University of Queensland, Queensland, Australia, ⁶Pfizer Inc, New York, NY, ⁷Pfizer Inc, Groton, CT, ⁸Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Patients with RA often receive concomitant treatment with glucocorticoids (GCs) to control…
Abstract Number: 1635 • 2015 ACR/ARHP Annual Meeting
Development of New Bioassay System Measuring Inhibitory Strength of IL-6/STAT3 Signal Under Tocilizumab Treatment in Rheumatoid Arthritis Patients
Shuntaro Saito¹, Katsuya Suzuki¹, Kunihiro Yamaoka¹ and Tsutomu Takeuchi², ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Tocilizumab (TCZ) is a IL-6 receptor blockade, administered intravenously every 4 weeks and efficiently inhibits IL-6/STAT3 signaling pathway. We have previously reported the usefulness…
Abstract Number: 1636 • 2015 ACR/ARHP Annual Meeting
Clinical Benefit of 1-Year Certolizumab Pegol Treatment in MTX-Naïve, Early Rheumatoid Arthritis Patients Is Maintained after Discontinuation up to 1 Year
Tatsuya Atsumi¹, Kazuhiko Yamamoto², Tsutomu Takeuchi³, Hisashi Yamanaka⁴, Naoki Ishiguro⁵, Yoshiya Tanaka⁶, Katsumi Eguchi⁷, Akira Watanabe⁸, Hideki Origasa⁹, Toshiharu Shoji¹⁰, Osamu Togo¹¹, Toshiyuki Okada¹², Désirée van der Heijde¹³, Nobuyuki Miyasaka¹⁴ and Takao Koike¹⁵, ¹Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ²Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ³Keio University School of Medicine, Tokyo, Japan, ⁴Tokyo Women's Medical University, Tokyo, Japan, ⁵Department of Orthopedic Suregery, Nagoya University Hospital, Nagoya, Japan, ⁶The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁷Department of Immunology and Rheumatology, Nagasaki University, Nagasaki, Japan, ⁸Tohoku University, Sendai, Japan, ⁹Division of Biostatistics and Clinical Epidemiology, University of Toyama School of Medicine, Toyama, Toyama, Japan, ¹⁰Department of Clinical Research and Development, Otsuka Pharmaceutical Co., Ltd, Shinagawa-ku, Tokyo, Japan, ¹¹Biometrics Group, UCB Pharma, Tokyo, Japan, ¹²Astellas Pharma Inc., Japan, Tokyo, Japan, ¹³University Hospital, Maastricht, Netherlands, ¹⁴Tokyo Medical and Dental University, Tokyo, Japan, ¹⁵Medicine II, Hokkaido University Graduate School of Medicine, Sapporo, Japan
Background/Purpose: Efficacy and safety of certolizumab pegol (CZP) treatment in combination with optimized-dose MTX in Japanese MTX-naïve early rheumatoid arthritis (RA) patients (pts) with poor…
Abstract Number: 1637 • 2015 ACR/ARHP Annual Meeting
TNFi Combination Therapy, Switching and Persistence Patterns By Longitudinal Disease Activity Strata in Patients with Rheumatoid Arthritis
Leslie Harrold^1,2, George W. Reed^1,2, Natalie Boytsov³, Carol L. Gaich³, Marc Mason⁴, Xiang Zhang³, Cynthia J. Larmore³, Sabrina Deveikis⁴ and Andre B. Araujo³, ¹University of Massachusetts Medical School, Worcester, MA, ²Corrona, LLC, Southborough, MA, ³Eli Lilly and Company, Indianapolis, IN, ⁴Corrona, LLC., Southborough, MA
Background/Purpose: The purpose of this study was to describe the treatment patterns in biologic naïve initiators of TNF-inhibitors (TNFi) based on their disease activity over…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].